3D bioprinting is revolutionizing tissue engineering and the future of health. BICO's Bioprinting business area provides the most cutting edge technologies, to the brightest minds, to enable this future.
On this page
What is Bioprinting?
What is Bioprinting?
Bioprinting is an additive manufacturing process similar to conventional 3D printing – it uses a digital file as a blueprint to print an object in a variety of geometries and sizes. But unlike 3D printing, bioprinters print with cells and biomaterials, creating organ-like structures that mimic physiological conditions
Bioprinting has massive potential to revolutionize the fields of tissue engineering, drug discovery and regenerative medicine. Bioprinted tissue enable researchers to test potential treatments and evaluate efficacy in earlier stages, and providing a more realistic model of cellular function. In time, new drugs and treatments can be developed following a process designed to minimize failures, reduce animal testing and reach clinical trials faster.
Bioprinting helps address the major challenge faced by cell biologists around the world. The challenge of recapitulating the in vivo environment. By controlling both macro and micro features, bioprinters enable researchers to fine tune geometries, cell positioning, biomechanical gradients and many more parameters that provide the ideal biological environment for cells to thrive.
Applications of Bioprinting
Unfortunately, 21 patients per day die due to organ transplant shortages. Being able to bioprint organs could help clinicians keep up with patients or eliminate the list entirely. While this solution is far down the line, it is one of the most impactful possibilities in the field.
Bioprinting by numbers
A research group at Gothenburg University has developed an in-depth understanding of stem cells, and how they can be reprogrammed to create life changing therapies.
CELLINK’s INKREDIBLE+™ bioprinter and Advanced BioMatrix’s LifeInk® 200 type I collagen were used in a groundbreaking nasal cartilage bioprinting study recently published in the Journal of Tissue Engineering.
CELLINKs BIO X 3D Bioprinter is helping accelerate the healing of diabetic foot ulcers (DFU) with 3D bioprinted patches that enable sustained release of antibiotics directly to the wound area.
Researchers at Johns Hopkins University conducted a study on the human stem cells potential use as a treatment for degenerative muscle disorders.
Antibiotic resistance is one of the greatest threats to global health, food safety and development. With this in mind, researchers of the Imperial College London developed a novel fiber-optics Raman spectroscopy sensor for the label-free identification of bacteria.
CTIBiotech, an innovative R&D firm based in Lyon, France, is using CELLINK’s BIO X 3D bioprinter to produce in vitro full skin models from human cells.
Rensselaer Polytechnic Institute has developed a bioink of human cells and animal collagen using CELLINK’s BIO X bioprinter.
University of Technology in Sydney is developing bioprinted heart tissue on demand with patient-specific cells to minimize the risk of transplant rejection.
Ronawk mass-produces adult stem cells using bioprinters from CELLINK paving the way for the possibility to grow and transplant patients’ own stem cells without the need for the immunosuppressive drugs that are usually required after an organ donation.
Good Clean Love is advocating for the use of a 3D model of human tissue developed by MatTek as a more relevant alternative to testing women’s personal care products on animals.
Researchers from Boston University have manufactured a microfluidic heart-on-a chip platform, a model of a human heart, paving the way for fundamental studies of heart tissue and eventually enables the fabrication of tissue that can be implanted into the beating heart
Cornell Medical College is developing nanomaterials to more efficiently deliver oncology drugs to the brain, eliminate cancerous tumors and, ultimately, improve the survival rate of patients with DIPG tumors among other brain cancers.
Carcinotech bioprints patient-specific test models with cells from biopsy samples and has benefited greatly from CELLINK’s expertise in the field.
Featured Product Offering
With six printheads in total for unparalleled versatility, the BIO X6 bioprinter from CELLINK makes it easier to produce more complex and sophisticated constructs with a broader range of materials, cells and crosslinking tools. With many possible combinations, the six slots significantly increase throughput, cut down on print time and improve experiment efficiency. The BIO X6 is the preferred system for researchers seeking to enhance 3D cell culturing, tissue engineering, disease modeling and drug screening applications.
MatTek’s patented EpiDerm system is a leading in vitro testing technology for dermal toxicologists and formulation scientists. With multiple ECVAM validations and OECD accepted test guidelines, EpiDerm is a proven in vitro model system for chemical, pharmaceutical and skin care product testing.
The Quantum X bio, a true demonstration of bioconvergence. A product that is co-developed by CELLINK and Nanoscribe, it is the first of its kind 3D bioprinter, enabling submicron printing resolution, and raising the bar for high precision 3D bioprinting. Powered by Two Photon Polymerization (2PP), the system is the premier tool for miniaturizing bioprinting, redefining what it means to work within advanced biomedical applications, including tissue engineering and regenerative medicine.
3D Bioprinting Set To Propel Medical Research Forward
3D printing techniques are being used in medical research to establish more personalized treatment approaches and accelerate drug discovery. The technology is unlocking the potential of 3D cell culture approaches to better replicate the human body, gain a greater understanding of various cell types and, ultimately, develop patient- and organ-specific treatment pathways.
How 3D Bioprinters Are Advancing Cancer Research
Although the past decade has yielded significant reductions in the cancer death rate around the world, cancer is still the second leading cause of death globally, accounting for about 10 million deaths in 2020. This sobering statistic makes the search for more efficient cancer solutions an important priority for researchers the world over. While animal models have advanced our understanding of the molecular mechanisms associated with cancer and its progression, therapeutics developed with these interspecies models often fail in clinical trials because the efficacy results do not translate to humans.
Fighting to End Animal Testing
Drug and cosmetic developers are still mandated to test on animals, even if it doesn’t benefit the science. This leads to the experimentation on and death of hundreds of millions of primates, dogs, rabbits, mice and other animals. With 3D bioprinting, BICO is replacing outdated methods for drug discovery to end animal testing once and for all.